Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement
Bullock, R.; Passmore, P.; Wilkinson, D.; Howard, R.; Jones, R.
Bmj 320(7233): 511-512
2000
ISSN/ISBN: 0959-8138 PMID: 10678874 Document Number: 513582
Document emailed within 1 workday
Related Documents
Gillen, T.E.; Gregg, K.M.; Yuan, H.; Kurth, M.C.; Krishnan, K.R. 2001: Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease Psychopharmacology Bulletin 35(2): 83-96Mackell, J.A.; Ferris, S.H.; Mohs, R.; Schneider, L.; Galasko, D.; Whitehouse, P.; Schmitt, F.; Sano, M.; Thal, L.J. 1997: Multicenter evaluation of new instruments for Alzheimer's disease clinical trials: summary of results. The Alzheimer's Disease Cooperative Study Alzheimer Disease and Associated Disorders 11 Suppl. 2: S65-S69
Ferris, S.H.; Mackell, J.A. 1997: Behavioral outcomes in clinical trials for Alzheimer disease Alzheimer Disease and Associated Disorders 11(Suppl): S10-S15
Peng, Y.; Li, P-ping.; Li, L.; Zhang, Y.; Hou, W-zhen.; Cui, D-dan.; Li, J.; Wang, L.; Wang, Q-li.; Wang, X-liang. 2016: Progress of clinical trials in Alzheimer's disease drugs Yao Xue Xue Bao 51(8): 1185-1195
Caban-Holt, A.; Bottiggi, K.; Schmitt, F.A. 2005: Measuring treatment response in Alzheimer's disease clinical trials Geriatrics Suppl: 3-8
Vetel, J.M. 1993: Clinical trials in Alzheimer disease. Methodological problems: what application for what indication? Therapie 48(3): 207-210
Scheinin, N.M.; Scheinin, M.; Rinne, J.O. 2011: Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 55(3): 265-279
de Silva, H.A.; Pathmeswaran, A.; Gunatilake, S.B. 2005: Efficacy of rivastigmine on activities of daily living in Sri Lankan patients with Alzheimer disease and on improving caregiver burden: a prospective study Ceylon Medical Journal 50(3): 106-109
Lipczyńska-Łojkowska, W.; Ryglewicz, D.; Jedrzejczak, T.; Jakubowska, T.; Kotapka-Minc, S.ła.; Sienkiewicz-Jarosz, H.; Bochyńska, A. 2004: The effect of rivastigmine on cognitive functions and regional cerebral blood flow in Alzheimer's disease and vascular dementia: follow-up for 2 years Neurologia i Neurochirurgia Polska 38(6): 471-481
Weigmann, K. 2015: The ethics of global clinical trials: in developing countries, participation in clinical trials is sometimes the only way to access medical treatment. what should be done to avoid exploitation of disadvantaged populations? Embo Reports 16(5): 566-570
Morris, J.C.; Mohs, R.C.; Rogers, H.; Fillenbaum, G.; Heyman, A. 1988: Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease Psychopharmacology Bulletin 24(4): 641-652
Nasab, N.M.; Bahrammi, M.A.; Nikpour, M.R.A.; Rahim, F.; Naghibis, S.N. 2012: Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia JPMA. Journal of the Pakistan Medical Association 62(7): 677-680
Andrieu, S.; Rascol, O.; Lang, T.; Grandjean, H.; Vellas, B. 2006: Disease modifying trials in Alzheimer disease: methodological and statistical issues Journal of Nutrition Health and Aging 10(2): 116-117
Vercelletto, M. 2002: Scales used for therapeutic trials in Alzheimer's disease Revue Neurologique (Paris) 158(8-9): 857-861
González-Gutiérrez, J.L.; Gobartt, A.L. 2007: Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study) Revista de Neurologia 44(12): 705-710
Touchon, J.; Portet, F.; Gauthier, S. 2006: Prevention trials in Alzheimer disease: one step forward? Neurology 67(9 Suppl 3): S21-S22
Scoles, L.; Silagy, C. 1993: Logistics of participation in clinical trials Australian Family Physician 22(3): 380-381
Spaight, S.J.; Nash, S.; Finison, L.J.; Patterson, W.B. 1984: Medical oncologists' participation in cancer clinical trials Progress in Clinical and Biological Research 156: 49-61
Wilkie, R.; Jordan, J.L.; Muller, S.; Nicholls, E.; Healey, E.L.; van der Windt, D.A. 2011: Measures of social function and participation in musculoskeletal populations: Impact on Participation and Autonomy (IPA), Keele Assessment of Participation (KAP), Participation Measure for Post-Acute Care (PM-PAC), Participation Objective, Participation Subjective (POPS), Rating of Perceived Participation (ROPP), and the Participation Scale Arthritis Care and Research 63(Suppl 11): S325-S336
Wilkie, R.; Jordan, J.L.; Muller, S.; Nicholls, E.; Healey, E.L.; van der Windt, D.A. 2011: Measures of social function and participation in musculoskeletal populations: Impact on Participation and Autonomy (IPA), Keele Assessment of Participation (KAP), Participation Measure for Post-Acute Care (PM-PAC), Participation Objective, Participation Subjective (POPS), Rating of Perceived Participation (ROPP), and the Participation Scale Arthritis Care and Research 63(Suppl 11): S325-S336